AU2021378944A1 - Combinations of metap2 inhibitors and cdk4/6 inhibitors for the treatment of cancer - Google Patents

Combinations of metap2 inhibitors and cdk4/6 inhibitors for the treatment of cancer Download PDF

Info

Publication number
AU2021378944A1
AU2021378944A1 AU2021378944A AU2021378944A AU2021378944A1 AU 2021378944 A1 AU2021378944 A1 AU 2021378944A1 AU 2021378944 A AU2021378944 A AU 2021378944A AU 2021378944 A AU2021378944 A AU 2021378944A AU 2021378944 A1 AU2021378944 A1 AU 2021378944A1
Authority
AU
Australia
Prior art keywords
inhibitor
cancer
cdk4
pharmaceutically acceptable
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021378944A
Other languages
English (en)
Inventor
Bradley J. CARVER
Peter Cornelius
James Shanahan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SynDevRX Inc
Original Assignee
SynDevRX Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SynDevRX Inc filed Critical SynDevRX Inc
Publication of AU2021378944A1 publication Critical patent/AU2021378944A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
AU2021378944A 2020-11-11 2021-11-10 Combinations of metap2 inhibitors and cdk4/6 inhibitors for the treatment of cancer Pending AU2021378944A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063112217P 2020-11-11 2020-11-11
US63/112,217 2020-11-11
US202163166060P 2021-03-25 2021-03-25
US63/166,060 2021-03-25
PCT/US2021/058775 WO2022103834A1 (en) 2020-11-11 2021-11-10 Combinations of metap2 inhibitors and cdk4/6 inhibitors for the treatment of cancer

Publications (1)

Publication Number Publication Date
AU2021378944A1 true AU2021378944A1 (en) 2023-06-15

Family

ID=78821168

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021378944A Pending AU2021378944A1 (en) 2020-11-11 2021-11-10 Combinations of metap2 inhibitors and cdk4/6 inhibitors for the treatment of cancer

Country Status (8)

Country Link
US (1) US20230404963A1 (https=)
EP (1) EP4243807A1 (https=)
JP (1) JP2023550035A (https=)
KR (1) KR20230117574A (https=)
AU (1) AU2021378944A1 (https=)
CA (1) CA3198173A1 (https=)
MX (1) MX2023005501A (https=)
WO (1) WO2022103834A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250127759A1 (en) * 2021-12-02 2025-04-24 Pfizer Inc. Methods and dosing regimens comprising a cdk2 inhibitor for the treatment of cancer
CA3264343A1 (en) * 2022-08-10 2024-02-15 Syndevrx, Inc. METAP2 INHIBITORS FOR THE TREATMENT OF PULMONARY FIBROSIS

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
US20130137831A1 (en) * 2010-05-25 2013-05-30 John S. Petersen Optimized drug conjugates
CA3239447A1 (en) * 2016-01-11 2017-07-20 Syndevrx, Inc. Treatment for tumors driven by metabolic dysfunction
WO2019070755A1 (en) * 2017-10-02 2019-04-11 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR DETECTING AND MODULATING A GENETIC SIGNATURE OF IMMUNOTHERAPY RESISTANCE IN CANCER
JP2022512826A (ja) * 2018-10-26 2022-02-07 シンデブルックス，インコーポレイティド ＭｅｔＡＰ２阻害剤のバイオマーカーとその応用

Also Published As

Publication number Publication date
US20230404963A1 (en) 2023-12-21
MX2023005501A (es) 2023-07-27
EP4243807A1 (en) 2023-09-20
JP2023550035A (ja) 2023-11-30
WO2022103834A1 (en) 2022-05-19
KR20230117574A (ko) 2023-08-08
CA3198173A1 (en) 2022-05-19

Similar Documents

Publication Publication Date Title
US20230190721A1 (en) Solid forms of fxr agonists
JP6416339B2 (ja) 選択的ｐｉ３ｋデルタ阻害剤
US10898490B2 (en) Method for treating cancer
KR102292853B1 (ko) 이중 선택적 pi3 델타 및 감마 키나아제 억제제
AU2013312319B2 (en) Method of treating leukemia
US12419846B2 (en) Biomarkers of METAP2 inhibitors and applications thereof
TW201811794A (zh) (s)-7-(1-丙烯醯基六氫吡啶-4-基)-2-(4-苯氧基苯基)-4,5,6,7-四氫吡唑並[1,5-a]嘧啶-3-甲醯胺的晶型、其製備和用途
CN111303133A (zh) 降解ezh2蛋白的小分子化合物
AU2013358876A1 (en) Methods and compositions for inhibiting cnksr1
EP4243807A1 (en) Combinations of metap2 inhibitors and cdk4/6 inhibitors for the treatment of cancer
WO2015197006A1 (zh) 一种取代的氨基酸硫酯类化合物、其组合物及应用
US10039769B2 (en) Substituted triazolobenzodiazepines
CN116887836A (zh) 用于治疗癌症的metap2抑制剂和cdk4/6抑制剂的组合
WO2021222350A1 (en) Methods of use for single molecule compounds providing multi-target inhibition to treat covid-19
US20220041629A1 (en) Estrogen receptor targeting antagonists
WO2026024772A2 (en) Oxynitidine derivatives as tyrosyl dna phosphodiesterase inhibitors and radiosensitizers
TW201708239A (zh) 經取代的氨基酸硫酯類化合物、其組合物及應用